Myelofibrosis News and Research

RSS
Celgene announces fiscal 2009 third-quarter results

Celgene announces fiscal 2009 third-quarter results

IND for Cytopia's CYT387 clears the FDA review

IND for Cytopia's CYT387 clears the FDA review

Discovery of mutant genes in acute lymphoblastic leukemia

Discovery of mutant genes in acute lymphoblastic leukemia

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Experimental drug successfully blocks mutation in bone marrow cancers

Experimental drug successfully blocks mutation in bone marrow cancers

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

S*BIO initiates trials of oral JAK2 inhibitor for hematological malignancies

S*BIO initiates trials of oral JAK2 inhibitor for hematological malignancies

Anemia drugs linked with leukemic transformation in patients with primary myelofibrosis

Anemia drugs linked with leukemic transformation in patients with primary myelofibrosis

UIC receives $20 million NCI grant to research blood disorders

UIC receives $20 million NCI grant to research blood disorders

MPD Foundation funds research for incurable blood disorders

MPD Foundation funds research for incurable blood disorders

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation

Discovery of a single mutation responsible for a number of blood disorders

Discovery of a single mutation responsible for a number of blood disorders

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

Impaired cognitive and motor function following stem cell transplantation for severe blood disorders can improve

Impaired cognitive and motor function following stem cell transplantation for severe blood disorders can improve

Thalidomide's role in fighting blood disorders, such as multiple myeloma

Thalidomide's role in fighting blood disorders, such as multiple myeloma